1. Home
  2. NEUP vs COCP Comparison

NEUP vs COCP Comparison

Compare NEUP & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuphoria Therapeutics Inc.

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.94

Market Cap

20.6M

Sector

N/A

ML Signal

HOLD

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

N/A

Current Price

$1.16

Market Cap

21.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEUP
COCP
Founded
1996
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.6M
21.6M
IPO Year
2002
2011

Fundamental Metrics

Financial Performance
Metric
NEUP
COCP
Price
$3.94
$1.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$21.00
$6.00
AVG Volume (30 Days)
197.7K
67.7K
Earning Date
05-23-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.65
EPS
N/A
N/A
Revenue
$15,649,448.00
$12,712,091.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.19
$0.76
52 Week High
$21.31
$2.03

Technical Indicators

Market Signals
Indicator
NEUP
COCP
Relative Strength Index (RSI) 54.18 66.39
Support Level $3.75 $0.92
Resistance Level $4.15 $1.22
Average True Range (ATR) 0.17 0.08
MACD 0.03 0.02
Stochastic Oscillator 33.90 81.09

Price Performance

Historical Comparison
NEUP
COCP

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Share on Social Networks: